ldn-211904 is an inhibitor of erythropoietin-producing hepatocellular carcinoma (eph) receptors.erythropoietin-producing hepatocellular carcinoma (eph) receptors, a group of highly conserved transmembrane proteins composed of multiple domains, participate in various cell signaling pathways. so far, 16 eph receptors have been identified in vertebrates, which can be divided into two major classes (epha and ephb) based on sequence similarity. mammals including humans have 14 eph receptors (epha1–epha8, epha10, ephb1–ephb4 and ephb6).
previous study found that ldn-211904, a 4-piperidinyl analog, retained significant ephb3 inhibitory activity, and also had greater aqueous solubility due to the presence of a basic amine. ldn-211904 was profiled for functional inhibitory activity against a panel of 288 kinases and the results showed that ldn-211904 was quite selective for tyrosine kinases. the only noted exceptions were the three serine/threonine kinases p38a, p38b, and qik. in addition, only ldn-211904 showed moderate selectivity among the tyrosine kinases and little selectivity verses other epha and ephb subtypes, except for epha6 and epha7. moreover, ldn-211904 demonstrated the best stability with a t1/2 of 348 min and a clint of 4 μl/min/mg protein [1].
[1] qiao, l. ,choi, s.,case, a., et al. structure-activity relationship study of ephb3 receptor tyrosine kinase inhibitors. bioor. med. chem. lett. 19(21), 6122-6126 (2009).
